Stampa Pagina

18 marzo 2016

We would like to invite applications for one position of research under the active group led by Dr. Paolo Palma.

We are looking for a post‐doctoral researcher with a strong research background and experience in immunology and transcriptomics, with a publication track record relevant for the search of novel correlates of viral control in early‐treated HIV‐infected children.

The researcher will undertake a challenging project in an internationally renowned environment (EPIICAL Consortium) and will have the option of studying novel B cell pathways. This project will involve the development of innovative technologies such as the Fluidigm BioMark HD system and novel tools to address the mechanisms via which host immunity controls HIV viral dynamics in the paediatric HIV field.
The project is designed to allow the applicant to play a major role in determining its direction, as well as benefit from extensive international collaboration with other members of the EPIICAL Consortium.

Interested applicants should send a single PDF file containing a cover letter, CV, one‐page statement of research interests and contact information for three references to direzione.scientifica@opbg.netquoting the code OPBG2016/01.

Review of applications will begin immediately and will continue until the position is filled. Employment of the successful candidate will be contingent upon the successful completion of a preemployment clinical background check.

A starting 12‐months (renewable up to 36 months) clinical research position starting in early 2016 will be awarded to the successful candidate.

Position and salary will depend on qualification and experience.
Please contact Dr Paolo Palma ( for any further information

The research project is supported by the PENTA Foundation.


Reference Code Department/Laboratory/Unit Requested degree Research fields Deadline for submission

OPBG 2016/01

Congenital and Perinatal Infections Research Unit

MD or PhD in Biological Sciences

Novel correlates of viral control in early-treated HIV-infected children